CSI Market
Sign In | Register

180 Life Sciences (ATNF) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access ATNF quarterly Cash Flow →
Tracking cash flow results across 180 Life Sciences to Dec 31 2021 helps illustrate how Dec 31 2025's cash generation has responded to changing business conditions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-894.05
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Impairment of Long-Lived Assets Held-for-use0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Sale of Assets and Asset Impairment Charges0.00
Share-based Compensation213.45
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants83.20
Interest Income Earned On Marketable Securities Held In Trust Account-
Loss On Issuance Of Convertible Promissory Notes-
Derivative Gain Loss On Derivative Net-
Cost Depreciation Amortization And Depletion-
Gains Losses On Restructuring Of Debt-
Bad Debtrecovery Expense-
Modification Of Stock Award-
Gain On Exchange Rate Transactions-
Deferred Other Tax Expense Benefit-
Liabilities Fair Value Adjustment-
Equity Fair Value Adjustment-
Amortization Of Stock Options-
Amoritization Of Stock Options-
Offering Costs Allocated To Warrant Liabilities-
Loss On Saledisposal Of Property And Equipment-
Change In Fair Value Of Accrued Issuable Equity-
Crypto Asset Unrealized Gain Loss Nonoperating0.31
Change In Fair Value Of Cryptocurrency-0.22
Gain On Settlement Of Liabilities-
Income taxes0.00
Gain (Loss) on Sale of Derivatives-0.24
Increase (Decrease) in Accounts Receivable0.50
Accounts Payable1.35
Increase (Decrease) in Accrued Liabilities0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets3.31
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net418.24
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations-7.75
Net Cash flow from Operating Activities-26.05
Investing Activities
Capital Expenditures-244.28
Sale of Capital Items134.27
Short-term Investments Proceeds0.00
Payments to Acquire Marketable Securities-4.63
Real Estate Investments0.00
Interest Income Released From Trust Account To Pay Taxes-
Noncash Merger Related Costs-
Payment Of Common Stock Redemptions Payable-
Repayment Of Advances From Related Party-
Repayment Of Loans Payable-
Payments To Purchase Of Nonmarketable Securities-
Restricted Cash and Investments Increase (Decrease)0.00
Payments to Acquire Loans Receivable0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-127.63
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings500.00
Long-term debt - repayments-598.05
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-40.20
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock303.76
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net-0.15
Other net-7.20
Increase In Due To Related Party-
Stock Redeemed Or Called During Period Value-
Proceeds From Promissory Note Target Company-
Redemptions Of Common Stock-
Shares Issued For Cash Net Of Issuance Costs-
Offering Costs In Connection With Sale Of Common Stock And Warrants-
Payments For Loan-
Proceed From Loans-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations-
Repayment Of Loans Payable Related Parties-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents1.98
Proceeds From Exercise Of July2022 Prefunded Warrants-
Proceeds From Exercise Of December2022 Prefunded Warrants-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities158.15
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-136.06
Total Cash Flow4.47
4 historic quarters locked

Sign in to unlock the full 180 Life Sciences cash flow history.

Sign In Create Free Account

About Forum Markets Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001213900-26-037888

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License